Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR
This study is investigating a new medicine called Secukinumab for people who have polymyalgia rheumatica (PMR) or giant cell arteritis (GCA). These are conditions that cause inflammation and pain. The main purpose of this early-stage study is to understand how the body handles the medicine and whether it is safe and tolerable. Researchers want to learn how much of the medicine stays in the body and for how long. This type of study, often called a Phase 1 study, is focused on gathering basic information about the medicine in a small group of people.
At a glance
What is this study about?
This study is looking into a medication called Secukinumab, which is being explored as a possible treatment for two conditions: polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). Both of these conditions involve inflammation, often causing pain and stiffness, especially in the muscles and joints. GCA, in particular, can affect blood vessels.
The main goal of this early-stage research is to understand how Secukinumab acts inside the human body. Researchers want to find out how the body absorbs, processes, and gets rid of the medicine. They also want to see if the medicine is safe and doesn't cause too many unwanted side effects. This kind of study helps scientists learn important basic information about new medications before they can be tested in larger groups of people.
By gathering this information, doctors and scientists can decide if Secukinumab has the potential to be a helpful treatment for PMR or GCA in the future. It's a crucial step in developing new medicines, ensuring that they are as safe and effective as possible.
Key takeaways
- This study is for people with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA).
- It's testing an early-stage medicine called Secukinumab.
- The main goals are to check how the medicine works in the body and if it's safe.
- You must be 18 years or older to take part; both men and women are welcome.
- Participation involves medical checks, blood tests, and receiving the study medicine.
- You can stop participating at any time if you change your mind.
Who may be eligible?
To be considered for this study, you must be an adult aged 18 years or older. There is no upper age limit, meaning people of all adult ages can potentially take part. Both men and women are welcome to participate in this research.
Currently, we only know these basic requirements. Usually, studies like this also have more specific rules about your health, any other medicines you take, or if you have certain other medical conditions. For example, you would probably need to have a confirmed diagnosis of either polymyalgia rheumatica (PMR) or giant cell arteritis (GCA).
If you are interested, a healthcare professional involved in the study would go through all the detailed requirements with you to see if you are a good fit. They would check your medical history and current health carefully.
- Are you 18 years old or older?
- Do you have a diagnosis of polymyalgia rheumatica (PMR)?
- Do you have a diagnosis of giant cell arteritis (GCA)?
- Are you able to attend regular appointments for the study?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part, you would receive the study medication, Secukinumab, under close medical supervision. The study would involve several visits to a clinic or hospital for health checks, blood tests, and to make sure the medication is having the expected effects and no unexpected side effects. You would likely have regular blood samples taken to measure how the medicine moves through your body.
The researchers would keep a close eye on your health and any changes you experience. The total duration of your participation would depend on the study plan, but early-stage studies often involve a number of visits over a period of weeks or months, followed by some check-up calls or visits. You would be fully informed about the exact schedule before you agree to take part.
Potential risks and benefits
Locations (4)
- —Spain
- —Czechia
- —Portugal
- —Italy
Common questions
What are polymyalgia rheumatica (PMR) and giant cell arteritis (GCA)?
They are conditions that cause inflammation, usually leading to pain and stiffness in muscles and joints. GCA specifically affects blood vessels.
What is Secukinumab?
It's the name of the medicine being studied. Researchers want to understand how it works and if it's safe for people with PMR or GCA.
What does 'Human Pharmacology (Phase I)' mean?
It means this is a very early stage of testing a new medicine in people. The main goal is to check how the medicine behaves in the body and if it's safe.
Will I get better if I join this study?
While it's a possibility, the main goal of this early study is to gather information about the medicine's safety and how it works, not primarily to treat your condition. Personal benefit is not guaranteed.
Do I have to pay to join the study?
No, participating in a clinical trial does not typically involve any costs for you as a patient. All study-related medication and assessments are usually covered.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.